AbbVie (ABBV) Q3 Earnings Lift Guidance As Debt Concerns Linger

AbbVie just dropped its Q3 2026 report and the stock barely flinched, up about 1.4% to US$294.89 by the close. That is a muted move for a business that just printed US$17.4b in quarterly revenue and lifted full year adjusted earnings guidance to a midpoint of US$13.97 per share. The market is treating this like a routine beat, but the underlying message is louder. A richer net margin over the past year and a high 50.6x trailing P/E now collide with lingering worries about debt and negative equity.

Love AbbVie’s rich margins and earnings guidance but uneasy about the leverage and negative equity overhang? Consider screening for drugmakers that pair healthy profitability with cleaner balance sheets in our list of solid balance sheet and fundamentals stocks (24 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$17,404m vs. US$15,776m (up about 10.3%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$4,218m vs. US$176m (very large year over year increase)
• Basic EPS (Q3 2026 vs. Q3 2025): US$2.38 vs. US$0.10 (very large jump, more than 20x higher)
• Trailing 12-Month Net Margin (Q3 2026 vs. prior year): 15.6% vs. 3.9% (margin much stronger over the past year)

Earnings grab headlines, but investors who care about what AbbVie is actually worth usually spend more time on the cash flowing through the business. Those cash flows can tell a different story to reported profit in any single quarter.

On AbbVie’s numbers, if you focus on cash generation rather than just this year’s big swing in earnings, the stock could be a dramatic 41% undervalued.

AbbVie’s Post Humira Engine Clears Key Hurdles

AbbVie is often framed as a test of whether new drugs can truly replace Humira and Imbruvica. That ambition is laid out clearly.

"The key requirement for AbbVie is successfully executing on its pipeline and business development so that new immunology, oncology and neuroscience drugs replace revenue from declining products such as Humira and Imbruvica."

Immunology revenue of about US$34.9b for 2026, led by Skyrizi at US$21.8b and Rinvoq at US$11.2b, now meaningfully exceeds Humira’s shrinking US$683m quarterly haul. Neuroscience at roughly US$3.4b with fast growing Parkinson’s and migraine products adds further proof that replacement is happening, not just promised.

Execution Risks Surface In Oncology And Pricing

On the flip side, concerns focus on whether competition and regulation will chip away at AbbVie’s newer pillars.

"Imbruvica sales fell 29.4% operationally in the recent quarter due to pricing rules and competitive share pressure. Similar pressure spreading to other AbbVie oncology products could offset growth from newer assets and limit segment contribution to revenue and earnings."

Oncology revenue of about US$1.7b grew only 0.9% operationally as Imbruvica declined 26.1%. Gains from Venclexta, Epkinly and Elahere largely just patch the hole. That sluggish segment outcome, despite strong immunology and neuroscience, shows competitive and pricing headwinds are already visible rather than theoretical.

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for.

Hunt For Mispriced Earnings Power

AbbVie just showed how a big earnings story can leave the share price moving only modestly. The real opportunity is in finding stocks that could be undervalued before the market closes that gap.

• Company 1 - 28% below our estimate - supplies diagnostic gear utilities adopt as grid modernization and electrification increase pressure on aging infrastructure.
• Company 2 - 29% below our estimate - sells AI centric networking and data infrastructure when enterprises shift on premises workloads beyond basic cloud subscriptions.
• Company 3 - 21% below our estimate - builds optical packages for AI data centers as customers move more bandwidth heavy compute to photonics platforms.

Those are three of them. See the full list of 30 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com